布罗达卢马布用于治疗中度至重度的牛皮:一位专家德尔菲共识声明
Maria Concetta Fargnoli1,2, Federico Bardazzi3, Luca Bianchi4,5
1Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Journal of clinical medicine
|May 27, 2023
概括
意大利皮肤科医生制定了共识声明,建议使用布罗达卢马布 (brodalumab),一种介素-17RA抑制剂,用于治疗中度至重度的牛皮. 这些指导方针有助于有效管理患者.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布罗达卢马布是一种向介素-17RA的单克隆抗体,已在欧洲批准用于中度至重度的牛皮.
- 牛皮是一种慢性炎症性皮肤疾病,需要有效的治疗策略.
研究的目的:
- 在意大利皮肤科医生中建立Delphi共识文件,用于意大利皮肤科医生在中度至重度的牛皮中使用布罗达卢马布.
- 确定布罗达卢马布治疗的关键症状和管理原则.
主要方法:
- 一个指导委员会根据文献和临床经验起草了17份声明.
- 32名意大利皮肤科医生参与了使用5点利克特等级的修改后的Delphi共识过程.
- 通过两轮投票和一个虚拟会议,这些声明被改进为主要原则和共识声明.
主要成果:
- 在第一轮会议后,在17个声明中,就15个达成初始共识 (88.2%).
- 第二轮投票在5个主要原则中的4个和10个共识声明中的8个方面达到了80%的共识.
- 建立了由5个主要原则和10个共识声明组成的最终清单.
结论:
- 该共识文件提供了意大利中度至重度牛皮管理中的布罗达卢马布的关键指示.
- 这些陈述将有助于皮肤科医生优化布罗达卢马布治疗策略.
- 这些发现支持基于证据的临床实践,用于牛皮的生物治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
178
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
178
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
225
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
225
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
205
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
205
COPD: Management Using Bronchodilators and Corticosteroids
256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
199
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
199


